Earnings Downgrade, page-2

I think they had a lot of good news in a very short time which helped the SP run. I did think the market would have high expectations based on how well they bedded down Metrics.

CSL has runs on the board, Mayne has a new strategy with targeting generics which I think is great as what they were doing with Doryx would earn them $10's of M's while the generic strategy could earn them $100's of M's. That is why the PE is close to CSL's as CSL is more mature while Mayne could be considered a growth stock currently.

The retrace is occurring but long-term this stock is on the money IMO. I do think it will be $2 in a couple of years. That is obviously dependent on how many generic approvals they get (I'd be interested to know more details about the development pipeline transparency concerns as their slides seem quite open to me) but target markets are large, they are generating good profits, paying down debt and being less reliant on Doryx which is good